Pds Biotechnology Corp 8-K Filing
Ticker: PDSB · Form: 8-K · Filed: Dec 2, 2025 · CIK: 1472091
| Field | Detail |
|---|---|
| Company | Pds Biotechnology Corp (PDSB) |
| Form Type | 8-K |
| Filed Date | Dec 2, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00033 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Pds Biotechnology Corp (ticker: PDSB) to the SEC on Dec 2, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.00033 (ch registered Common Stock, par value $0.00033 per share PDSB The Nasdaq Capital M).
How long is this filing?
Pds Biotechnology Corp's 8-K filing is 2 pages with approximately 457 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 457 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2025-12-02 08:35:43
Key Financial Figures
- $0.00033 — ch registered Common Stock, par value $0.00033 per share PDSB The Nasdaq Capital M
Filing Documents
- ef20060301_8k.htm (8-K) — 28KB
- ef20060301_ex99-1.htm (EX-99.1) — 15KB
- image00003.jpg (GRAPHIC) — 3KB
- 0001140361-25-043889.txt ( ) — 176KB
- pdsb-20251202.xsd (EX-101.SCH) — 4KB
- pdsb-20251202_lab.xml (EX-101.LAB) — 21KB
- pdsb-20251202_pre.xml (EX-101.PRE) — 16KB
- ef20060301_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On December 2, 2025, PDS Biotechnology Corporation issued a press release announcing that its request for a Type C Meeting with the U.S. Food and Drug Administration has been accepted by the agency, and the meeting has been scheduled to occur this month. A copy of the press release is filed herewith as Exhibit 99.1 and incorporated by reference herein.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release Dated December 2, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document). Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PDS BIOTECHNOLOGY CORPORATION Date: December 2, 2025 By: /s/ Frank Bedu-Addo, Ph.D. Name: Frank Bedu-Addo, Ph.D. Title: President and Chief Executive Officer